Medacta Group SA

SWX:MOVE Stock Report

Market Cap: CHF 2.2b

Medacta Group Valuation

Is MOVE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MOVE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MOVE (CHF110.8) is trading above our estimate of fair value (CHF79.85)

Significantly Below Fair Value: MOVE is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MOVE?

Key metric: As MOVE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MOVE. This is calculated by dividing MOVE's market cap by their current earnings.
What is MOVE's PE Ratio?
PE Ratio42.1x
Earnings€56.21m
Market Cap€2.36b

Price to Earnings Ratio vs Peers

How does MOVE's PE Ratio compare to its peers?

The above table shows the PE ratio for MOVE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average62.7x
MED Medartis Holding
151.9x51.7%CHF 612.5m
METN Metall Zug
7.5x-29.6%CHF 510.8m
STMN Straumann Holding
61.4x20.9%CHF 17.7b
SOON Sonova Holding
29.8x8.8%CHF 17.9b
MOVE Medacta Group
42.1x18.4%CHF 2.2b

Price-To-Earnings vs Peers: MOVE is good value based on its Price-To-Earnings Ratio (42.1x) compared to the peer average (62.7x).

Price to Earnings Ratio vs Industry

How does MOVE's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MOVE 42.1xIndustry Avg. 28.9xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: MOVE is expensive based on its Price-To-Earnings Ratio (42.1x) compared to the European Medical Equipment industry average (28.9x).

Price to Earnings Ratio vs Fair Ratio

What is MOVE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MOVE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio42.1x
Fair PE Ratio30.9x

Price-To-Earnings vs Fair Ratio: MOVE is expensive based on its Price-To-Earnings Ratio (42.1x) compared to the estimated Fair Price-To-Earnings Ratio (30.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MOVE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 110.80
CHF 139.71
+26.1%
4.2%CHF 149.20CHF 131.15n/a5
Nov ’25CHF 113.60
CHF 139.63
+22.9%
4.2%CHF 149.11CHF 131.07n/a5
Oct ’25CHF 122.40
CHF 138.53
+13.2%
3.9%CHF 147.93CHF 132.44n/a7
Sep ’25CHF 130.00
CHF 140.13
+7.8%
3.8%CHF 150.12CHF 134.40n/a7
Aug ’25CHF 126.00
CHF 140.13
+11.2%
3.8%CHF 150.12CHF 134.40n/a7
Jul ’25CHF 123.00
CHF 139.19
+13.2%
4.2%CHF 148.77CHF 129.61n/a7
Jun ’25CHF 122.80
CHF 143.01
+16.5%
5.6%CHF 155.92CHF 131.46n/a7
May ’25CHF 111.40
CHF 143.01
+28.4%
5.6%CHF 155.92CHF 131.46n/a7
Apr ’25CHF 122.40
CHF 142.18
+16.2%
5.4%CHF 154.22CHF 130.04n/a7
Mar ’25CHF 127.00
CHF 140.59
+10.7%
7.3%CHF 156.49CHF 126.46n/a7
Feb ’25CHF 131.20
CHF 138.68
+5.7%
7.0%CHF 152.47CHF 125.02n/a7
Jan ’25CHF 125.60
CHF 133.43
+6.2%
10.8%CHF 152.89CHF 110.76n/a5
Dec ’24CHF 116.80
CHF 132.35
+13.3%
12.0%CHF 156.22CHF 113.18n/a5
Nov ’24CHF 108.00
CHF 132.35
+22.5%
12.0%CHF 156.22CHF 113.18CHF 113.605
Oct ’24CHF 115.80
CHF 125.20
+8.1%
10.1%CHF 142.98CHF 114.01CHF 122.403
Sep ’24CHF 124.00
CHF 128.43
+3.6%
11.8%CHF 152.39CHF 113.21CHF 130.004
Aug ’24CHF 126.60
CHF 128.43
+1.4%
11.8%CHF 152.39CHF 113.21CHF 126.004
Jul ’24CHF 121.80
CHF 113.93
-6.5%
15.1%CHF 142.93CHF 91.61CHF 123.005
Jun ’24CHF 115.40
CHF 103.57
-10.3%
6.6%CHF 111.63CHF 92.70CHF 122.804
May ’24CHF 119.80
CHF 103.57
-13.5%
6.6%CHF 111.63CHF 92.70CHF 111.404
Apr ’24CHF 99.20
CHF 103.57
+4.4%
6.6%CHF 111.63CHF 92.70CHF 122.404
Mar ’24CHF 100.60
CHF 106.79
+6.2%
4.5%CHF 111.99CHF 99.33CHF 127.004
Feb ’24CHF 99.60
CHF 106.39
+6.8%
2.6%CHF 110.50CHF 102.87CHF 131.204
Jan ’24CHF 103.00
CHF 106.02
+2.9%
3.1%CHF 109.36CHF 100.91CHF 125.604
Dec ’23CHF 102.20
CHF 106.02
+3.7%
3.1%CHF 109.36CHF 100.91CHF 116.804
Nov ’23CHF 88.80
CHF 108.27
+21.9%
5.5%CHF 117.43CHF 101.14CHF 108.004

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Siemens Healthineers

€55.1b

Through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide.

SHL

€46.32

7D

-1.4%

1Y

n/a

Becton Dickinson

US$66.7b

Develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

912061

US$238.02

7D

0%

1Y

-2.2%

Abbott Laboratories

US$203.6b

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.

ABT

US$93.50

7D

0%

1Y

2.7%